Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Average Recommendation of "Buy" by Brokerages

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) have received an average rating of "Buy" from the eight ratings firms that are covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $24.71.

Several brokerages have recently issued reports on TEVA. UBS Group cut their price target on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a research note on Thursday, June 26th. Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Truist Financial initiated coverage on Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a "buy" rating and a $25.00 target price on the stock. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and increased their target price for the company from $21.00 to $23.00 in a research note on Monday, May 12th. Finally, Bank of America increased their target price on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, May 8th.

Teva Pharmaceutical Industries Trading Down 0.5%

Shares of TEVA traded down $0.07 during trading hours on Friday, hitting $15.38. 14,134,433 shares of the stock traded hands, compared to its average volume of 11,701,027. The company has a current ratio of 1.06, a quick ratio of 0.74 and a debt-to-equity ratio of 2.45. Teva Pharmaceutical Industries has a 1-year low of $12.47 and a 1-year high of $22.80. The firm has a market capitalization of $17.64 billion, a PE ratio of -96.13, a price-to-earnings-growth ratio of 0.91 and a beta of 0.62. The business has a fifty day moving average of $16.89 and a 200-day moving average of $16.67.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%. The business had revenue of $4.18 billion for the quarter, compared to analyst estimates of $4.34 billion. During the same quarter in the prior year, the firm posted $0.61 earnings per share. The firm's revenue for the quarter was up .3% compared to the same quarter last year. Analysts expect that Teva Pharmaceutical Industries will post 2.5 EPS for the current year.

Insider Activity

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of the stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total value of $105,626.12. Following the completion of the sale, the executive vice president directly owned 9,989 shares in the company, valued at $170,012.78. This represents a 38.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.49% of the stock is owned by company insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Large investors have recently modified their holdings of the business. Oarsman Capital Inc. bought a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter worth about $29,000. Marshall & Sterling Wealth Advisors Inc. bought a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $44,000. Golden State Wealth Management LLC bought a new position in shares of Teva Pharmaceutical Industries during the first quarter worth about $39,000. New Age Alpha Advisors LLC bought a new position in shares of Teva Pharmaceutical Industries during the first quarter worth about $43,000. Finally, Sound Income Strategies LLC grew its holdings in shares of Teva Pharmaceutical Industries by 3,715.8% during the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company's stock worth $49,000 after buying an additional 2,824 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.